Skip to main content

Table 2 Summary of initial treatment delivered among 284 patients

From: Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study

EGFR mutation Mt – (n= 163) Mt + (n= 121)
  IIIB IV IIIB IV
  (n= 19) (n= 144) (n= 6) (n= 115)
  No. % No. % No. % No. %
Treatment         
 Platinum doublet 4 3 114 70 2 2 54 45
 Monotherapy 0   30 18 0   11 9
 EGFR-TKI 0   0   0   50 41
 Chemoradiotherapy 15 9 0   4 3 0  
Specific regimens         
 Cisplatin-pemetrexed 1   24 15 1   9 7
 Carboplatin-paclitaxel 3   52 32 0   27 22
 Carboplatin-paclitaxel+ bev 0   2   0   2  
 Other platinum doublets 0   36 22 1   12 10
 Gefitinib 0   0   0   41 34
 Erlotinib 0   0   0   7 6
 Docetaxel 0   16 10 0   3  
 Vinorelbine 0   5   0   2  
 Others 0   24 15 0   6  
  1. Mt+: mutant EGFR, Mt-: wild-type EGFR, bev: bevacizumab.